Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Muscle-invasive Urothelial Cancer of the Bladder 1

Interventions

Cyclophosphamide 516Bevacizumab 487Carboplatin 424pembrolizumab 384Paclitaxel 384Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 295Nivolumab 247Doxorubicin 243Dexamethasone 239Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 200Etoposide 187Cetuximab 184Lenalidomide 176Pemetrexed 175Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 165Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Transurethral Resection of Bladder × Clear all
NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

NYU Langone Health

Phase 2 Active not recruiting
60 enrolled 11 charts
Genitourinary

Muscle-invasive Urothelial Cancer of the Bladder

NCT00262951 2017-12-28

Chemoradiation in Locally Advanced Pancreatic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
23 enrolled 8 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡